Drug intelligence / Profile preview

SSGJ-706 + bevacizumab + XELOX

Development stage: Unknown
Lead developer: Shenyang Sunshine Pharmaceutical Co., LTD.
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

SSGJ-706 + bevacizumab + XELOX is a combination therapy regimen being developed by Shenyang Sunshine Pharmaceutical Co., Ltd. for the treatment of advanced gastrointestinal cancers. This multi-targeted approach combines **SSGJ-706**, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor to enhance anti-tumor immune responses; **bevacizumab**, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis; and **XELOX**, a standard chemotherapy regimen consisting of capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum-based agent). The combination is currently being evaluated in Phase II clinical trials for indications including gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal cancer, aiming to leverage the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy.

Other names: SSGJ-706 + bevacizumab + capecitabine + oxaliplatin

Targets

PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on SSGJ-706 + bevacizumab + XELOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSGJ-706 + bevacizumab + XELOX.

Explore the full profile